Researchers unsure whether the new hepatitis C drug’s entry into the U.S. market will drive down prices.
Another pharmaceutical company appears headed to market with
a drug that cures hepatitis C genotype 1, without interferon and ribavirin, in
just 12 weeks.
Research published today in The Journal
of the American Medical Association (JAMA) showed a combination of
Bristol-Myers Squibb drugs daclatasvir, asunaprevir, and beclabuvir cured
hepatitis C in 93 percent of 112 study participants with cirrhosis who had not
previously been treated.
The drug combination also eliminated the hepatitis virus in
87 percent of 90 participants who had treatment in the past that didn’t work.
When ribavirin was added, the success rate climbed to 93 percent.
Labels: asunaprevir, daclatasvir, daclatasvir+ asunaprevir (ASV) and beclabuvir (BCV)